Neutral Torrent Pharma; target of Rs 4970: Motilal Oswal
Motilal Oswal's research report on Torrent Pharma
Torrent Pharma (TRP) delivered slightly better-than-expected revenue/EBITDA (+3%/5%) for the quarter. Earnings were largely in line with estimates due to higher-than-expected tax rate for the quarter. TRP outperformed domestic formulation industry (IPM) growth by a wide margin, led by market share gains in chronic therapies, robust scale-up of Curatio portfolio, and healthy market share in the Semaglutide product. Notably, TRP outpaced the Brazilian branded generics market, led by new launches, volume growth, pricing, and inventory normalization.
Outlook
We value TRP at 52x 12-month forward earnings to arrive at a TP of INR4,970. We remain constructive on TRP's domestic growth prospects, expanding Semaglutide opportunity and potential earnings benefits from JB Pharma integration. Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions. Torrent Pharma_26102026_Motilal Oswal